JP2019500320A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500320A5
JP2019500320A5 JP2018522569A JP2018522569A JP2019500320A5 JP 2019500320 A5 JP2019500320 A5 JP 2019500320A5 JP 2018522569 A JP2018522569 A JP 2018522569A JP 2018522569 A JP2018522569 A JP 2018522569A JP 2019500320 A5 JP2019500320 A5 JP 2019500320A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
rsv
protein
virus
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500320A (ja
JP7311872B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/058976 external-priority patent/WO2017075125A1/en
Publication of JP2019500320A publication Critical patent/JP2019500320A/ja
Publication of JP2019500320A5 publication Critical patent/JP2019500320A5/ja
Priority to JP2023065428A priority Critical patent/JP2023100654A/ja
Application granted granted Critical
Publication of JP7311872B2 publication Critical patent/JP7311872B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522569A 2015-10-29 2016-10-27 キメラｒｓｖ、免疫原性組成物、及び使用方法 Active JP7311872B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023065428A JP2023100654A (ja) 2015-10-29 2023-04-13 キメラｒｓｖ、免疫原性組成物、及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562247962P 2015-10-29 2015-10-29
US62/247,962 2015-10-29
US201662334547P 2016-05-11 2016-05-11
US62/334,547 2016-05-11
PCT/US2016/058976 WO2017075125A1 (en) 2015-10-29 2016-10-27 Chimeric RSV, Immunogenic Compositions, and Methods of Use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023065428A Division JP2023100654A (ja) 2015-10-29 2023-04-13 キメラｒｓｖ、免疫原性組成物、及び使用方法

Publications (3)

Publication Number Publication Date
JP2019500320A JP2019500320A (ja) 2019-01-10
JP2019500320A5 true JP2019500320A5 (enExample) 2019-12-05
JP7311872B2 JP7311872B2 (ja) 2023-07-20

Family

ID=58630734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018522569A Active JP7311872B2 (ja) 2015-10-29 2016-10-27 キメラｒｓｖ、免疫原性組成物、及び使用方法
JP2023065428A Pending JP2023100654A (ja) 2015-10-29 2023-04-13 キメラｒｓｖ、免疫原性組成物、及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023065428A Pending JP2023100654A (ja) 2015-10-29 2023-04-13 キメラｒｓｖ、免疫原性組成物、及び使用方法

Country Status (10)

Country Link
US (2) US11235050B2 (enExample)
EP (1) EP3368547A4 (enExample)
JP (2) JP7311872B2 (enExample)
KR (1) KR20180085730A (enExample)
CN (1) CN108602858A (enExample)
BR (1) BR112018008708A2 (enExample)
CA (1) CA3003726A1 (enExample)
MX (1) MX2018005462A (enExample)
SG (1) SG11201803581VA (enExample)
WO (1) WO2017075125A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113322264B (zh) 2013-03-14 2024-05-31 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
KR20220041966A (ko) 2016-04-05 2022-04-01 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 용해성 융합-전 rsv f 단백질
CN110603262A (zh) 2017-04-04 2019-12-20 华盛顿大学 显示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途
AU2019228551B2 (en) 2018-02-28 2025-07-24 University Of Washington Self-assembling nanostructure vaccines
JOP20210106A1 (ar) * 2018-11-13 2023-01-30 Janssen Vaccines And Prevention B V بروتينات rsv f سابقة الاندماج مستقرة
WO2020167813A1 (en) 2019-02-11 2020-08-20 Emory University Chimeric rsv and hmpv f proteins, immunogenic compositions, and methods of use
WO2022217085A1 (en) * 2021-04-08 2022-10-13 Codagenix Inc. Method of eliciting an immune response against respiratory syncytial virus
US12304929B2 (en) * 2021-04-12 2025-05-20 Sk Bioscience Co., Ltd. Recombinant RSV live vaccine strain and the preparing method thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AT401526B (de) 1993-02-10 1996-09-25 Scheirer Winfried Reagenzlösung zur stabilisierung der lumineszenz bei der luciferasemessung
EP1394259A3 (en) 1994-07-18 2004-04-14 Karl-Klaus Prof. Dr. Conzelmann Recombinant infectious non-segmented negative strand RNA virus
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6923971B2 (en) 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
US6214805B1 (en) 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
ATE451451T1 (de) 1996-07-15 2009-12-15 Us Gov Health & Human Serv Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
WO2001089562A1 (en) * 2000-05-25 2001-11-29 Medimmune, Inc. F-protein epitope-based vaccine for respiratory syncytial virus infection
WO2004087062A2 (en) 2003-03-28 2004-10-14 Medimmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
EA011878B1 (ru) 2003-12-24 2009-06-30 Де Стат Дер Недерланден, Вертегенвордигд Дор Де Министер Ван Волксгезондхейд, Велзейн Ен Спорт Респираторно-синцитиальный вирус с перекрестно компенсированным геномным дефицитом
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US8772256B2 (en) 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
US9476032B2 (en) 2007-03-30 2016-10-25 The Research Foundation For The State University Of New York Attenuated viruses useful for vaccines
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
PE20110394A1 (es) 2008-11-05 2011-06-22 Merck Sharp & Dohme Virus sincitial respiratorio vivo atenuado
WO2010077717A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Modified rsv f proteins and methods of their use
PL3178490T3 (pl) 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
WO2011046925A1 (en) 2009-10-12 2011-04-21 Technovax, Inc. Respiratory syncytial virus (rsv) virus-like particles (vlps)
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
ES2651143T3 (es) * 2011-05-13 2018-01-24 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
WO2013006797A1 (en) 2011-07-06 2013-01-10 Nanobio Corporation Human respiratory syncytial virus vaccine
US8816081B2 (en) 2012-08-06 2014-08-26 Basf Se Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells
HRP20230694T1 (hr) 2013-02-08 2023-10-13 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Smanjenje ljudskog respiratornog sincicijskog virusa prema ljestvici genoma deoptimizacijom kodon-para
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
CN105473604B (zh) 2013-03-13 2021-01-22 美国政府(由卫生和人类服务部的部长所代表) 融合前rsv f蛋白和其用途
CN113322264B (zh) 2013-03-14 2024-05-31 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
US9060975B2 (en) * 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions

Similar Documents

Publication Publication Date Title
JP2019500320A5 (enExample)
Kim et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection
US11389523B2 (en) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
Lee et al. Mechanisms of cross-protection by influenza virus M2-based vaccines
JP2017503482A5 (enExample)
JP2017522907A5 (enExample)
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
CN109310750B (zh) 编码传染性喉气管炎病毒和传染性法氏囊病病毒抗原的重组非致病性马立克氏病病毒构建体
US7244435B2 (en) DNA vaccine expressing HA1 of equine-2 influenza virus
JP6802813B2 (ja) アヒル腸炎ウイルス及びその使用
CN104293741A (zh) 一种呼吸道合胞病毒病毒样颗粒疫苗及其制备方法和应用
JP2021500876A (ja) 複数の異種抗原をコードする組換え非病原性マレック病ウイルス構築物
JP5675789B2 (ja) 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型
WO2020215350A1 (zh) 禽流感与禽腺病毒4型二联基因工程亚单位疫苗及其制备方法
CN104031889A (zh) 表达传染性法氏囊病毒vp2蛋白的重组火鸡疱疹病毒疫苗及应用
Ying et al. Construction and immunological characterization of CD40L or GM-CSF incorporated Hantaan virus like particle
WO2005054451A1 (ja) 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
CN104353070B (zh) 一种鸡传染性支气管炎病毒的基因工程亚单位疫苗及其制备方法
CN107344969B (zh) 一种纳米流感疫苗及构建方法和应用
WO2023236822A1 (zh) H5n6禽流感广谱性疫苗的开发及其应用
CN113430178B (zh) 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用
Allam et al. Perspective vaccines for emerging viral diseases in farm animals
RU2358981C2 (ru) Универсальная вакцина против вируса гриппа птиц
CN103316357B (zh) 携带rsv基因的重组流感病毒嵌合疫苗及其制备方法
Mu et al. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA)